Metastatic hormone receptor-positive breast cancer in CDK 4/6 era: An outcome audit

Autor:	Govind Babu, G.V. Giri, Rajeev Krishnappa Lakkavalli, Jitendra Kumar Pehalajani, Lokesh N Kadabur, Suresh Babu, Venkatesh Tirumala, Linu Abraham Jacob, D Loknatha, Smitha Saldanha, A H Rudresha
Rok vydání:	2021
Předmět:	Oncology Clinical audit Adult medicine.medical_specialty Receptor ErbB-2 medicine.medical_treatment Breast Neoplasms Metastasis Breast cancer Cyclin-dependent kinase Internal medicine medicine Humans Radiology Nuclear Medicine and imaging Neoplasm Metastasis Protein Kinase Inhibitors Aged Retrospective Studies Clinical Audit biology business.industry Cancer Cyclin-Dependent Kinase 4 General Medicine Cyclin-Dependent Kinase 6 Middle Aged medicine.disease Prognosis Metastatic breast cancer Survival Rate Receptors Estrogen Hormone receptor biology.protein Female Hormone therapy business Receptors Progesterone Follow-Up Studies
Zdroj:	Journal of cancer research and therapeutics. 17(4)
ISSN:	1998-4138
Popis:	The treatment landscape of metastatic hormone receptor (HR) positive breast cancer has been changed in recent years. Availability of CDK 4/6 inhibitor and other hormone therapy has changed the treatment algorithm for these patient, we retrospectively analyzed our metastatic HR positive breast cancer patients.In this study, we retrospectively analyzed the case records of hr positive metastatic breast cancer patient treated at department of medical oncology from October 2016 to September 2018. Demographical characteristics, site of metastasis, objective response and clinical benefit response and toxicity profile were analyzed.We treated a total of 178 patients of MBC with HT at our center during the study period. One hundred fifty-two patients received HT alone (control group) and 26 patients received HT and CDK 4/6 inhibitor (study group). The median age of patients was 56 and 58 years in the control group and study group. The ORR was 41.7 versus 57.9 (95% CI [1.01-2.56]), and the CBR was 66.1% versus 78.9%; (CI [1.18-3.56]) (P0.05) of the patients in control and study groups, respectively.Among patients with HR-positive, advanced breast cancer, hormone therapy is efficacious addition of CDK 4/6 inhibitor improve the efficacy with tolerable side effects.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c5d8daf7e52dc7e94d9002b47714ac3 https://pubmed.ncbi.nlm.nih.gov/34528554 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.